title: Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question-Reply.
authors.affiliation: Berry Consultants, LLC, Austin, Texas2Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston.
authors.forename: Donald A
authors.initials: DA
authors.lastname: Berry
mesh_terms: D001943:Breast Neoplasms; D006801:Humans; D020360:Neoadjuvant Therapy; D018719:Erb-b2 Receptor Tyrosine Kinases
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases